RYTM Rhythm Pharmaceuticals Inc.

24.4
+0.27  (+1%)
Previous Close 24.13
Open 24.13
Price To Book 4.64
Market Cap 842,167,025
Shares 34,515,042
Volume 13,864
Short Ratio
Av. Daily Volume 256,368

NewsSee all news

  1. Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

    -- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for

  2. Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update due September 25, 2019.
Setmelanotide (basket)
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 3 data due 2020.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome
Phase 3 trial met primary endpoint - August 7, 2019.
Setmelanotide
Leptin Receptor Deficiency Obesity
Phase 3 trial met primary endpoint - August 7, 2019.
Setmelanotide
POMC deficiency obesity

Latest News

  1. Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

    -- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for

  2. Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of